WORLD / Science & Health

First RSV vaccine caps 60-year search to stem pervasive lung illness

An undated photo provided by the U.S. Centers for Disease Control and Prevention of a transmission electron microscopic image of the respiratory syncytial virus, or R.S.V. The Food and Drug Administration on Wednesday approved GSK’s vaccine for the RSV for adults who are 60 and older, the company said. | CENTERS FOR DISEASE CONTROL AND PREVENTION / VIA THE NEW YORK TIMES

By Suzi Ring
Bloomberg

May 4, 2023

For 60 years, doctors and scientists searched for a vaccine against a common virus that, while sometimes deadly, is little known to the public. The hunt is over.

The U.S. Food and Drug Administration cleared GSK’s shot against respiratory syncytial virus on Wednesday. The product will go on sale in the coming weeks for older adults.

Medical breakthroughs rarely come alone, and this one is no exception. GSK, seeking to reassert its role as a key vaccine industry player after falling behind in COVID-19, will likely be forced to battle it out with one of the biggest pandemic winners, Pfizer, within weeks.

First RSV vaccine caps 60-year search to stem pervasive lung illness

In your social network

In your inbox

In your social network

In your inbox